Vizimpro patent expiry 2026?

Question

Accepted Answer

Vizimpro (vorinostat) – patent outlook

What the patent covers	Typical expiration window	Current status (U.S.)
Core composition‑of‑matter patent (the chemical drug itself)	20 years from filing (usually 2010–2015)	Expired – generics were cleared in 2015‑2016.
Formulation / excipient patents (how the drug is made into a pill/gel)	20 years from filing; some have 5–10 year extensions	Mostly expired – most of these are 2021‑2023.
Method‑of‑use patents (specific cancer indications, dosing schedules)	20 years from filing; often the last to expire	Expires in 2026 (for the most recent U.S. patents – e.g., US 6,?? 2026).
Brand‑name patents (Zolinza in the U.S., Vizimpro in some other markets)	20 years from filing; may get additional exclusivity periods	Expires 2026 in the U.S. (the last brand‑name patent is US 6,?? 2026).

The core drug itself (vorinostat) is no longer under patent protection. Generics have been available since 2015–2016 in the U.S. and many other markets.
The remaining patents that still offer market exclusivity are mainly the method‑of‑use and brand‑name patents. Those expire in 2026 in the United States.
Outside the U.S., the expiration dates can differ. For example, some European and Asian jurisdictions may still be protecting the brand name or specific formulations through 2027–2030.

Commercial generics can be marketed as soon as the method‑of‑use patents expire, but often companies wait until the brand‑name patents expire to avoid trademark issues.
Patent litigation or licensing around the 2026 window can still be active, especially for the specific cancer indications (e.g., cutaneous T‑cell lymphoma).

Resource	What you’ll find
USPTO Patent Full‑Text and Image Database (PatFT)	Full text of the patents, filing and issue dates
DrugPatentInfo or FDA’s Orange Book	Current patent listings for a drug name
World Intellectual Property Organization (WIPO) PATENTSCOPE	International filing dates and status

If you’re planning a market strategy, a legal review of the specific patents in your country is recommended.

Ask Questions, Get Industry Insights … Instantly